Tumor Volume Reduction Rate Predicts Pathologic Tumor Response of Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemotherapy alone: Results from a Prospective Trial

Jian Xiao, Zerong Cai, Wenyun Li, Zuli Yang, Jiaying Gong, Yan Huang, Yanhong Deng, Xiaojian Wu, Lei Wang, Junsheng Peng, Donglin Ren, Ping Lan, Jianping WangJournal of Cancer 2015 · DOI

Abstract

TVRR is correlated with TRG and overall downstage significantly in LARC patients treated with preoperative chemotherapy alone and shows great value in predicting favorable TRG and overall downstage with good sensitivity and specificity. It could be considered as a promising parameter candidate for efficacy evaluation.

Introduction

Locally advanced rectal cancer (LARC) is traditionally managed with neoadjuvant chemoradiotherapy followed by surgery. While effective, radiation therapy introduces long-term risks such as bowel dysfunction and impaired sphincter preservation. Recent clinical trials suggest that for some patients, neoadjuvant chemotherapy (nCT) alone might be sufficient. This shift necessitates a precise, non-invasive way to monitor treatment efficacy. This study explores the utility of the Tumor Volume Reduction Rate (TVRR), calculated via 3D MRI, as a predictor of pathological response in patients receiving nCT without the confounding effects of radiation-induced inflammation.

Methods

Data were analyzed from 80 eligible patients in the prospective FOWARC trial (NCT 01211210) with pathologically confirmed rectal adenocarcinoma (cT3-T4 and/or cN+). Patients received four cycles of mFOLFOX6 followed by surgery.

Manual tracing of tumor boundaries on a T2-weighted MRI slice for 3D volumetry.

Tumor volumes were determined using 3D-ROI MR Volumetry. Radiologists manually traced tumor boundaries on every slice of T2-weighted MRI scans both before and after chemotherapy to calculate a total 3D volume. TVRR was defined as the percentage change in volume. Post-surgical pathological response was assessed using Tumor Regression Grade (TRG) and TNM staging as the gold standard.

Results

The average volume reduction across the cohort was 51.7%. Statistical analysis revealed that TVRR is a robust predictor of favorable pathological outcomes.

Patient characteristics and their association with Tumor Volume Reduction Rate (TVRR).

Key findings include:

  • Predictive Accuracy: Through ROC analysis, a TVRR threshold of 65% was identified as optimal for predicting a favorable TRG (0/1), yielding a sensitivity of 0.704 and a specificity of 0.804.
  • Downstaging: Every 10% increase in TVRR was associated with a 179.3% increase in the odds of achieving overall downstaging.
  • Biological Correlation: Tumor differentiation significantly influenced shrinkage; well/moderately differentiated tumors showed a higher mean TVRR (53.3%) compared to poorly differentiated or mucinous adenocarcinomas (31.5%, P=0.040).

Discussion

The study highlights that TVRR is particularly accurate when radiation is excluded. In a "clean" chemotherapy-only environment, MRI volumetry more directly reflects tumor cell death without the interference of radiation-induced edema or fibrosis. While TVRR excelled at predicting primary tumor response (T-stage), it was not a significant predictor of lymph node (N-stage) downstaging, likely due to the inherent difficulty of distinguishing metastatic nodes from benign reactive nodes on MRI.

Conclusion

TVRR is a promising, non-invasive metric for evaluating the efficacy of neoadjuvant chemotherapy in LARC. A reduction of 65% or more serves as a reliable indicator of favorable pathological response, potentially allowing for more personalized, less toxic treatment strategies. Further large-scale trials are needed to validate these findings and correlate TVRR with long-term survival outcomes.

Summary updated

Abstract

TVRR is correlated with TRG and overall downstage significantly in LARC patients treated with preoperative chemotherapy alone and shows great value in predicting favorable TRG and overall downstage with good sensitivity and specificity. It could be considered as a promising parameter candidate for efficacy evaluation.
BibTeX
@article{xiao2015tumor,
  author = {Jian Xiao and Zerong Cai and Wenyun Li and Zuli Yang and Jiaying Gong and Yan Huang and Yanhong Deng and Xiaojian Wu and Lei Wang and Junsheng Peng and Donglin Ren and Ping Lan and Jianping Wang},
  title = {{Tumor Volume Reduction Rate Predicts Pathologic Tumor Response of Locally Advanced Rectal Cancer Treated with Neoadjuvant Chemotherapy alone: Results from a Prospective Trial}},
  journal = {Journal of Cancer},
  year = {2015},
  doi = {10.7150/jca.11738},
}
Figure